Cybin: Canaccord Bumps Price Target To US$7.00

Cybin Inc (NEO: CYBN) last month had a long month of news reports, the first being that they received conditional approval to list on the New York Stock Exchange, keeping the same ticker “CYBN”. Then a week later, the company announced the size of their overnight marketed public offering of $30 million, which consists of 8.82 million shares at a price of $3.40.

Cybin only has 6 analysts covering the stock with an average 12-month price target of $10, or a 250% upside. The street high sits at $15 from Stifel-GMP while the lowest comes in at $8. Out of the 6 analysts, 1 has a strong buy rating and the other 5 have buy ratings.

Last week, Canaccord raised their 12-month price target on Cybin to U$7 from U$6 and reiterated their buy rating, saying “with catalysts coming, newly NYSE-listed CYBN remains undervalued.” They believe now that the company is cashed up after the $30 million raised, the money will obviously help carry out the companies lead candidate trial of CYB001.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

CYB001 is a sublingual form of psilocybin for major depressive disorder. This candidate will be entering a Phase 2a trial in Jamaica, which data from the study could be available by the end of the year. That means the company could be ready to start Phase 2b trials in early 2022.

Canaccord raised their price target as they adjusted their operating expense estimates and removed the raise overhang that they believed would be happening in late February 2022, although they still expect additional raises in fiscal 2023 and 2024.

Canaccord assumes that the drug will be offered to 1-2 million patients in the US and that the starting price would be $20,000 for two treatments per year, which is expected to start in fiscal 2026.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Epic Gold Outlines 150,700 Indicated Ounces at 2.26 G/T in Updated Benoist Resource

Related News

Alphabet: Analyst Consensus Points To Q2 Revenues Of $69.95 Billion

Alphabet (NASDAQ: GOOGL) will be reporting its second quarter financial results on July 26th after...

Monday, July 25, 2022, 03:03:00 PM

Galaxy Digital Sees BMO Slash Price Target From $35 To $24

Galaxy Digital (TSX: GLXY) reported its first quarter financial results on Monday. The company said...

Thursday, May 12, 2022, 04:33:00 PM

Vintage Wine Estates Sees Canaccord Initiate Coverage With $17.00 Price Target

It’s been a pretty busy month for Vintage Wine Estates (NASDAQ: VWE), a SPAC that...

Monday, June 21, 2021, 03:49:00 PM

Kinross Gold: Canaccord Lowers Target After Higher Than Expected Costs

On July 28, Kinross Gold Corporation (TSX: K) reported their second quarter results. The company...

Friday, August 6, 2021, 10:07:00 AM

Canaccord Initiates On FuelCell Energy With $4.50 Price Target, Hold Rating

On December 9th, Canaccord Genuity initiated coverage on FuelCell Energy (NASDAQ: FCEL) with an $8.50...

Thursday, December 10, 2020, 03:39:00 PM